Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actoxumab/bezlotoxumab - Merck & Co

Drug Profile

Actoxumab/bezlotoxumab - Merck & Co

Alternative Names: 3D8; Bezlotoxumab/actoxumab; CDA-1/CDA-2; GS-CDA-1/MDX-1388; MBL-CDA1/MBL-CDB1; MDX-066 + MDX-1388; MDX-066/MDX-1388; MK-3415 + MK-6072; MK-3415/MK-6072; MK-3415A

Latest Information Update: 24 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex; University of Massachusetts Medical School
  • Developer Bristol-Myers Squibb; Merck & Co; University of Massachusetts Medical School
  • Class Antidiarrhoeals; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Clostridium difficile infections

Most Recent Events

  • 24 Jan 2018 No recent reports on development identified - Phase-III for Clostridium difficile infections in Japan, Finland, Sweden, Poland, Greece, Belgium, Italy, Czech Republic, United Kingdom, Austria, Spain, Portugal, Denmark, Germany and USA (IV)
  • 20 Sep 2015 Merck announces intention to submit regulatory applications in USA, European Union and Canada in 2015
  • 20 Sep 2015 Efficacy and adverse events data from the phase III MODIFY I and II trials in Clostridium difficile infections released by Merck
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top